The role of osteopontin as a biomarker in endometrial cancer has not been conclusively established. We evaluated the expression and potential of osteopontin as a biomarker for endometrial cancer. Real-time polymerase chain reaction and immunohistochemistry revealed osteopontin overexpression in endometrial cancer. The plasma osteopontin level in endometrial cancer was significantly higher than in healthy controls (P < 0.001). In FIGO stage I endometrial cancer, osteopontin correctly identified 18 of 29 cases (62.1%) that were not detected by CA125. By Cox multivariate analysis, osteopontin positivity was an independent prognostic factor for disease-free survival (hazard ratio = 3.18, P= 0.035).
Bibliographical noteFunding Information:
This work was supported, in part, by the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (7-2006-0153), a CMB-YUHAN research grant of Yonsei University College of Medicine for 2006 (6-2006-0030), and the Korea Research Foundation Grant funded by the Korean Government (MOEHRD, Basic Research Promotion Fund) (KRF-2006-311-e00339).
All Science Journal Classification (ASJC) codes
- Cancer Research